- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03243799
Effectiveness of a Psychoeducational Group Intervention in Patients With Depression and Physical Comorbidity (PsiCoDep)
Effectiveness of a Psychoeducational Group Intervention Conducted by Primary Health Care Nurses in Patients With Depression and Physical Comorbidity
The primary aim is to evaluate the effectiveness of an intervention based on a psychoeducational program carried out by primary care nurses, to improve the rate of remission and response of depression in patients with physical chronic illness (diabetes, COPD, asthma and / or ischemic heart disease). Secondarily, to assess the cost-effectiveness of the intervention, the effectiveness to improve the control of physical pathology, the impact on quality of life and the feasibility of the intervention.
Methods: a multicentre, randomized clinical trial, with two groups and 1 year follow-up evaluation. Economic evaluation study. We will study 504 patients (252 in each group), over 50 years assigned to 25 primary care teams (PC) from Catalonia (urban, semi-urban and rural) with major depression and with at least one of the diseases: diabetes mellitus type 2, chronic obstructive pulmonary disease, asthma, and / or ischemic heart disease. They will be distributed randomly into two groups. The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from PC, consisting of health education on chronic physical illness and depressive symptoms.
Main measurements: clinical remission of depression and / or response to intervention (Beck depression inventory: BDI-II). Secondary measures: improvement in control of chronic disease (blood test and physical parameters), drug compliance (test Morinsky-Green and number of packaging), quality of life (EQ-5D), medical service utilization (appointments and hospital admissions due to complications) and feasibility of the intervention (satisfaction and compliance). Evaluations will be masked and conducted at 0, 3 and 12 months. At 6 months, patients will receive a call from nurses.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Barcelona
-
Santa Margarida de Montbui, Barcelona, Spain, 08710
- Centre d'Atenció Primària (CAP) Santa Margarida de Montbui
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of at least one of the following diseases: type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma, and / or ischemic heart disease.
- Meet major depression criteria at the time of the study: Score above 13 on the BDI-II scale.
- Possibility of follow-up of one year by the same primary care team.
- At least read and write Spanish or Catalan.
Exclusion Criteria:
- Diagnosis of dementia or moderate or high cognitive impairment (5 or more errors according to the pfeiffer scale).
- Major depression with psychotic symptoms or with other serious psychiatric comorbidities.
- Moderate or high risk of suicide (6 or more points on the MINI suicide scale).
- Dependency disorders due to alcohol or other drug abuse.
- Advanced stage physical disease.
- Inability to travel to the center.
- Be receiving some psychological therapy by the Center of mental health (CSM) of reference
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention Group
The intervention group will participate in psychoeducational groups: 12 weekly 90-minute sessions led by two nurses from Primary Care, consisting of health education on chronic physical illness and depressive symptoms. Group psychoeducation. |
Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
|
NO_INTERVENTION: Control Group
Usual clinical care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in rate of remission of depression
Time Frame: At 12 months of follow-up
|
Changes in the score of the BDI-II scale
|
At 12 months of follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in rate of remission of depression
Time Frame: At 3 months of follow-up
|
Changes in the score of the BDI-II scale
|
At 3 months of follow-up
|
Changes in the control of DM2
Time Frame: At 12 months of follow-up
|
Changes in HbA1c
|
At 12 months of follow-up
|
Changes in the control of COPD
Time Frame: At 12 months of follow-up
|
Changes in FEV1
|
At 12 months of follow-up
|
Changes in the control of asthma
Time Frame: At 12 months of follow-up
|
Changes in FEV1
|
At 12 months of follow-up
|
Changes in the control of Ischemic heart disease
Time Frame: At 12 months of follow-up
|
Changes in LDL cholesterol
|
At 12 months of follow-up
|
Referrals to mental health
Time Frame: At 12 months of follow-up
|
Number of visits to mental health centers
|
At 12 months of follow-up
|
Record of therapeutic compliance
Time Frame: At 12 months of follow-up
|
Morisky-Green test
|
At 12 months of follow-up
|
Changes in the quality of life
Time Frame: At 12 months of follow-up
|
Measured by the EuroQol scale (EQ-5D)
|
At 12 months of follow-up
|
Quantification of the use of services
Time Frame: At 12 months of follow-up
|
Number of hospital admissions
|
At 12 months of follow-up
|
Satisfaction with the intervention
Time Frame: At 3 months of follow-up
|
Survey at the end of the intervention
|
At 3 months of follow-up
|
Adherence to the intervention
Time Frame: At 3 months of follow-up
|
Number of assisted sessions
|
At 3 months of follow-up
|
Qualitative changes of the state of mind at the end of the intervention
Time Frame: At 3 and 12 months of follow-up
|
better, equal or worse
|
At 3 and 12 months of follow-up
|
Qualitative changes of the state of health at the end of the intervention
Time Frame: At 3 and 12 months of follow-up
|
better, equal or worse
|
At 3 and 12 months of follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI16/01272
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedDepressive Disorder, Major Depressive DisorderUnited States
-
Samsung Medical CenterUnknownMajor Depressive Disorder, Anxiety DisorderKorea, Republic of
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
Clinical Trials on Group psychoeducation
-
Mackay Memorial HospitalCompleted
-
Ege UniversityCompletedSubstance-Related Disorders | Disease | Substance Use Disorders | Alcohol Use Disorder | Mental Disorders, SevereTurkey
-
Ege UniversityCompletedStress | Problems PsychosocialTurkey
-
Technical University of MunichCompletedSchizophrenia | Schizoaffective DisorderGermany
-
University of Western Ontario, CanadaCentre for Addiction and Mental Health; Women's College Hospital; Wharton Medical...CompletedMood Disorders | ObesityCanada
-
University of EdinburghNHS GrampianUnknown
-
Duke UniversityNational Institute of Mental Health (NIMH)CompletedSchizophrenia Spectrum and Other Psychotic Disorders | Mental Disorders, SevereTanzania
-
University of ArizonaCompletedSchizophrenia | Schizoaffective Disorder | Major Depression With Psychotic Features | Bipolar Disorder With Psychotic Features | Psychotic Disorder Not Otherwise Specified (NOS)United States
-
University School of Physical Education in WroclawFoundation for Senior Citizen Activation SIWY DYMCompletedDepression | Anxiety | Depressive SymptomsPoland
-
The Hong Kong Polytechnic UniversityHospital Authority, Hong Kong; Jilin Medical College, China; Taipei Medical University...CompletedSchizophreniaHong Kong, China, Taiwan